UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
批准号:
10645033
负责人:
KIM L.R. BROUWER
金额:
$74.43万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
未结题
起止时间:
2011-07-01 至 2026-06-30
中文摘要
摘要
北卡罗来纳大学教堂山分校(UNC)与杜克大学合作取得了成功
T32临床药理学博士后培训计划,以我们的卓越研究为基础
在药物发现、药物开发、药代动力学方面拥有世界级计划的环境/
药效学、儿科临床药理学和药物安全性。对临床药师的需求
是高的,我们在培训临床医生和科学家以满足不断增长的劳动力方面有着出色的记录
这一领域的需求。我们有一个优秀和多样化的申请者人才库,比
有资金的职位。此续订申请(11-15年)描述了我们的2年期培训计划(4个新的
实习生/年),它提供强大的领导力,来自多个学科的国际公认的导师
积极参与临床药理学,广泛的尖端技术和资源,以及
独特的协作环境和强有力的制度支持。这一项目的全国申请者池
该计划主要来源于医学专业培训计划中寻求临床职业道路的医学博士
药理学以及药学专业的高级临床/转化性研究培训。受训人员,由
个性化的发展计划和指导团队,完成临床药理学课程和
参与特定项目的活动,以获得当代临床药理学各方面的专业知识
研究为成功的学术、监管或行业职业生涯做准备,成为
未来几代临床药理学家。经验丰富的教师导师是根据他们的
在构成本培训计划核心的四个重点领域中至少一个领域的研究效率:药物
处置和行动;定量药理学/药物计量学和临床试验设计;个体化
治疗;药物引起的器官毒性。该培训计划的新内容包括更多关注
在精确剂量、使用真实数据和药物计量学方面;扩大临床试验计划
专业和创新领域的药理学培训;增加职业发展机会;
以及扩大与其他T32计划的合作。这一培训计划的一个独特之处在于
将重点放在临床药理学研究不足的领域,特别是儿科和药物安全性。这个
在我们的实习生群体中对临床药理学产生了浓厚的兴趣,在临床方面的投资是无与伦比的
北卡罗来纳大学和杜克大学的药理学研究资源,智力丰富的生物医学科学环境
研究三角园区和我们长期优秀的研究和培训基础设施相结合,创造了
无与伦比的临床药理学培训机会。
英文摘要
ABSTRACT
The University of North Carolina at Chapel Hill (UNC) in collaboration with Duke University has a successful
T32 postdoctoral training program in clinical pharmacology that builds on our exceptional research
environment with world-class programs in drug discovery, drug development, pharmacokinetics/
pharmacodynamics, pediatric clinical pharmacology, and drug safety. The demand for clinical pharmacologists
is high, and we have an outstanding track record of training clinician-scientists to meet the growing workforce
needs in this field. We have an excellent and diverse applicant pool with many more qualified applicants than
funded positions. This renewal application (Years 11-15) describes our 2-year training program (4 new
trainees/year), which offers strong leadership, internationally-recognized mentors from multiple disciplines who
are actively involved in clinical pharmacology, a wide-array of cutting edge technologies and resources, and a
uniquely collaborative environment with strong institutional support. The national applicant pool for this
program is derived primarily from MDs in medical specialty training programs seeking a career path in clinical
pharmacology, and also from PharmDs in advanced clinical/translational research training. Trainees, guided by
individualized development plans and mentoring teams, complete clinical pharmacology coursework and
engage in program-specific activities to gain expertise in all aspects of contemporary clinical pharmacology
research in preparation for successful academic, regulatory or industrial careers as leaders and mentors to
future generations of clinical pharmacologists. Experienced faculty mentors are chosen based on their
research productivity in at least one of four focus areas that form the core of this training program: Drug
Disposition and Action; Quantitative Pharmacology/Pharmacometrics & Clinical Trial Design; Individualized
Therapy; Drug-induced Organ Toxicity. New components of this training program include an increased focus
on precision dosing, use of real-world data, and pharmacometrics; pilot programs to expand clinical
pharmacology training in specialty and innovative areas; enhanced professional development opportunities;
and expansion of collaborations with other T32 programs. A unique feature of this training program continues
to be our focus on understudied areas in clinical pharmacology, specifically pediatrics and drug safety. The
keen interest in clinical pharmacology within our trainee pool, the unparalleled investment in clinical
pharmacology research resources at UNC and Duke, the intellectually-rich biomedical science environment of
Research Triangle Park, and our longstanding excellent research and training infrastructure combine to create
a moment of unsurpassed opportunity for training in clinical pharmacology.
期刊论文(86)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Injectable pH and Thermo-Responsive Hydrogel Scaffold with Enhanced Osteogenic Differentiation of Preosteoblasts for Bone Regeneration.
可注射的pH和热响应水凝胶支架,具有增强的骨骼再生前成骨细胞成骨分化。
DOI:
10.3390/pharmaceutics15092270
发表时间:
2023-09-02
期刊:
Pharmaceutics
影响因子:
5.4
作者:
[King JL, Shrivastava R, Shah PD, Maturavongsadit P, Benhabbour SR]
通讯作者:
Benhabbour SR
β blockers for heart failure: which works best?
β受体阻滞剂治疗心力衰竭:哪种效果最好?
DOI:
10.1136/bmj.f480
发表时间:
2013
期刊:
BMJ (Clinical research ed.)
影响因子:
--
作者:
[Mentz,RobertJ]
通讯作者:
Mentz,RobertJ
Improved survival and higher rates of surgical resection associated with hepatocellular carcinoma in children as compared to young adults.
与年轻人相比,儿童肝细胞癌的生存率更高,手术切除率更高。
DOI:
10.1002/ijc.34215
发表时间:
2022
期刊:
International journal of cancer
影响因子:
6.4
作者:
[Commander,SarahJane, Cerullo,Marcelo, Arjunji,Neha, Leraas,HaroldJ, Thornton,Steven, Ravindra,Kadiyala, Tracy,ElisabethT]
通讯作者:
Tracy,ElisabethT
DOI:
10.1002/jcph.1739
发表时间:
2021-03
期刊:
Journal of clinical pharmacology
影响因子:
2.9
作者:
[Commander SJ, Wu H, Boakye-Agyeman F, Melloni C, Hornik CD, Zimmerman K, Al-Uzri A, Mendley SR, Harper B, Cohen-Wolkowiez M, Hornik CP, Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee]
通讯作者:
Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee
DOI:
10.1002/jac5.1426
发表时间:
2021-06-01
期刊:
JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
影响因子:
--
作者:
[Morbitzer, Kathryn A., McLaughlin, Jacqueline E., Lee, Craig R.]
通讯作者:
Lee, Craig R.
共 40 条
Duke-UNC Collaborative Pediatric Clinical Pharmacology Postdoctoral Training Program
-
批准号:10400677
-
项目类别:
-
资助金额:$19.2万
-
财政年份:2021
-
负责人:KIM L.R. BROUWER
-
依托单位:
Duke-UNC Collaborative Pediatric Clinical Pharmacology Postdoctoral Training Program
-
批准号:10626740
-
项目类别:
-
资助金额:$18.51万
-
财政年份:2021
-
负责人:KIM L.R. BROUWER
-
依托单位:
Duke-UNC Collaborative Pediatric Clinical Pharmacology Postdoctoral Training Program
-
批准号:10173438
-
项目类别:
-
资助金额:$18.4万
-
财政年份:2021
-
负责人:KIM L.R. BROUWER
-
依托单位:
Mechanisms of Altered Hepatic Transport: Impact on Drug Therapy
-
批准号:9906256
-
项目类别:
-
资助金额:$56.94万
-
财政年份:2017
-
负责人:KIM L.R. BROUWER
-
依托单位:
Mechanisms of Altered Hepatic Transport: Impact on Drug Therapy
-
批准号:10406459
-
项目类别:
-
资助金额:$67.58万
-
财政年份:2017
-
负责人:KIM L.R. BROUWER
-
依托单位:
Mechanisms of Altered Hepatic Transport: Impact on Drug Therapy
-
批准号:10598589
-
项目类别:
-
资助金额:$60.78万
-
财政年份:2017
-
负责人:KIM L.R. BROUWER
-
依托单位:
Mechanisms of Altered Hepatic Transport: Impact on Drug Therapy
-
批准号:9277071
-
项目类别:
-
资助金额:$29.81万
-
财政年份:2017
-
负责人:KIM L.R. BROUWER
-
依托单位:
UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
-
批准号:10434641
-
项目类别:
-
资助金额:$71.06万
-
财政年份:2011
-
负责人:KIM L.R. BROUWER
-
依托单位:
UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
-
批准号:10090199
-
项目类别:
-
资助金额:$70.65万
-
财政年份:2011
-
负责人:KIM L.R. BROUWER
-
依托单位:
CLINICAL TRIAL: MODULATION OF TECHNETIUM-99M MEBROFENIN HEPATIC TRANSPORT TO RIT
-
批准号:7716839
-
项目类别:
-
资助金额:$0.53万
-
财政年份:2008
-
负责人:KIM L.R. BROUWER
-
依托单位:
MODULATION OF TECHNETIUM-99M MEBROFENIN HEPATIC TRANSPORT TO RITONAVIR
-
批准号:7625634
-
项目类别:
-
资助金额:$1.26万
-
财政年份:2006
-
负责人:KIM L.R. BROUWER
-
依托单位:
VALIDATION OF A METHOD TO QUANTITATE BILIARY EXCRETION IN HUMANS
-
批准号:7377415
-
项目类别:
-
资助金额:$0.27万
-
财政年份:2005
-
负责人:KIM L.R. BROUWER
-
依托单位:
QUANT OF TC-99M SESTAMIBI BILIARY EXCRETION IN HUMANS USING OROENTERIC CATHETER
-
批准号:7377556
-
项目类别:
-
资助金额:$1.02万
-
财政年份:2005
-
负责人:KIM L.R. BROUWER
-
依托单位:
DEVELOPMENT OF A MODEL TO PREDICT DRUG HEPATOTOXICITY
-
批准号:6840988
-
项目类别:
-
资助金额:$13.14万
-
财政年份:2004
-
负责人:KIM L.R. BROUWER
-
依托单位:
VALIDATION OF A METHOD TO QUANTITATE BILIARY EXCRETION IN HUMANS
-
批准号:7200196
-
项目类别:
-
资助金额:$0.53万
-
财政年份:2004
-
负责人:KIM L.R. BROUWER
-
依托单位:
DEVELOPMENT OF A MODEL TO PREDICT DRUG HEPATOTOXICITY
-
批准号:6932315
-
项目类别:
-
资助金额:$13.14万
-
财政年份:2004
-
负责人:KIM L.R. BROUWER
-
依托单位:
Validation of a Method to Quantitate Biliary Excretion in Humans
-
批准号:6980619
-
项目类别:
-
资助金额:$0.71万
-
财政年份:2003
-
负责人:KIM L.R. BROUWER
-
依托单位:
ALTERED HEPATIC DISPOSITION OF ANIONIC DRUGS: MECHANISM
-
批准号:3467623
-
项目类别:
-
资助金额:$9.75万
-
财政年份:1991
-
负责人:KIM L.R. BROUWER
-
依托单位:
ALTERED HEPATIC DISPOSITION OF ANIONIC DRUGS--MECHANISM
-
批准号:3467622
-
项目类别:
-
资助金额:$9.74万
-
财政年份:1991
-
负责人:KIM L.R. BROUWER
-
依托单位:
ALTERED HEPATIC DISPOSITION OF ANIONIC DRUGS-MECHANISMS
-
批准号:6635990
-
项目类别:
-
资助金额:$28.99万
-
财政年份:1991
-
负责人:KIM L.R. BROUWER
-
依托单位:
海外基金